Fused Aza-Aromatic Compounds Targeting Ras Ubiquitination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current proteasome inhibitors, while showing therapeutic effects on cancer, non-specifically affect protein degradation leading to strong toxic side effects due to their broad action on proteins, limiting their use in treating cancers associated with Ras overactivation.
Innovation Solution
Development of five-membered-fused-six-membered aza-aromatic ring compounds that specifically enhance ubiquitination degradation of Ras proteins by Nedd4-1, thereby inhibiting Ras activity and reducing tumor growth and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If proteasome inhibitors are used to treat cancer, then tumor growth is inhibited, but toxic side effects increase due to non-specific protein degradation
Solution Approach 1:
The patent introduces an intermediary mechanism (ubiquitination system with Nedd4-1 E3 ligase) to mediate Ras protein degradation specifically, rather than directly inhibiting the proteasome. The compound I enhances ubiquitination of Ras proteins, marking them for targeted degradation through the natural ubiquitin-proteasome pathway, thereby achieving cancer therapy with reduced off-target effects compared to direct proteasome inhibition
Solution Approach 2:
The invention applies local quality by creating selective action on Ras proteins through specific ubiquitination tagging. The compound I selectively promotes ubiquitination of Ras family proteins (H-Ras, K-Ras, N-Ras) while leaving other proteins unaffected, enabling localized therapeutic action on cancer-related pathways without global disruption of protein homeostasis
2Adaptability or versatility
If proteasome inhibitors non-specifically affect protein degradation, then broad protein breakdown occurs, but selectivity for Ras proteins decreases
Solution Approach 1:
Instead of directly inhibiting proteasome to achieve broad protein degradation, the invention inverts the approach by activating the ubiquitination system to selectively tag Ras proteins for degradation. This indirect method uses the cell's own quality control machinery to achieve selective protein breakdown, reversing the conventional direct inhibition strategy
Solution Approach 2:
The ubiquitination system serves as an intermediary that bridges the gap between the compound and the proteasome. Compound I enhances ubiquitin ligase activity, which then selectively marks Ras proteins for degradation, providing a controlled intermediate step that ensures selectivity while maintaining the ultimate degradation function
Data Source
Figure 1a~1b
Figure 2a~2c
Figure 3a~3b
AI summary
The invention relates to the field of medicinal chemistry, and to five-membered-fused-six-membered aza-aromatic ring compound, preparation method thereof, pharmaceutical composition and application thereof. In particular, the invention relates to a type of compounds capable of specifically enhancing ubiquitination degradation of Ras proteins, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with Ras activity in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.